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Is revascularization and limb salvage always the
best treatment for critical limb ischemia?
Mark R. Nehler, MD,a William R. Hiatt, MD,b and Lloyd M. Taylor, Jr, MD,c Denver, Colo; and Portland, Ore
Contemporary care of critical limb ischemia (CLI) con-
sists of near universal attempts at aggressive limb salvage. In
our opinion this approach is excessively lesion focused and
inadequately patient focused. Subgroups of the CLI popu-
lation currently undergoing extensive limb salvage efforts
may be better served with primary amputation or nonop-
erative management. We describe limitations in the knowl-
edge base underlying modern care of CLI.
First, our understanding of the natural history of CLI is
limited, with minimal ability to identify at-risk patients and
prevent disease progression. Most patients with symptom-
atic CLI have a tremendous disease burden, with poor
baseline function, including loss of ability to ambulate and
ability to live independently in many and abbreviated sur-
vival for most. Second, surgical treatment is graft and limb
focused, with only modest understanding of the effects of
treatment on patient morbidity and function. While surgi-
cal revascularization may prevent limb loss, this outcome
does not universally result in ambulation or functional
independence. Third, the advantage of revascularization
over primary amputation in patients who do not regain
independent ambulation is unclear. Fourth, the influence
of the extent of ischemic foot lesions on overall outcomes
has not been clearly defined. Finally, even if limb ischemia
can be relieved, a critical concern remains the high cardio-
vascular mortality risk in the CLI population. We do not
know if cardiovascular risk factor modification can modify
this natural history. We do not know whether a chronically
ischemic limb may actually increase the systemic risk for
myocardial infarction or stroke by inducing a proinflamma-
tory state and generating reactive oxygen species.1 What is
clear is that further study of CLI is needed in the form of
clinical trials with patient-oriented rather than limb-ori-
ented outcomes. We will briefly examine the reasons for
each of these statements. We will then propose an approach
to addressing acquisition of the data relevant to each issue,
including proposal for some relevant clinical trials.
NATURAL HISTORY OF CLI
One of the greatest deficiencies in the modern under-
standing of CLI is the antecedent natural history. The
Fontaine classification system designates CLI as either stage
I (asymptomatic), stage II (claudication), stage III (rest
pain), or stage IV (tissue necrosis). Many clinicians assume
that CLI progresses through these stages in a stepwise
manner. However, multiple natural history studies of Fon-
taine II disease reveal that in very few patients does claudi-
cation ever progress to CLI and that only 4% of patients are
at risk for limb loss.2 A paradoxical exception to this rule
occurs when patients with claudication undergo surgical
revascularization. Subsequent failure of the angioplasty or
bypass graft places that patient at increased risk for devel-
opment of CLI.3 Thus in most patients CLI progresses
directly from Fontaine stage I to stage III or IV. Dormandy
et al4 demonstrated in a multicenter prostaglandin trial that
50% of enrolled patients were asymptomatic 6 months
before major amputation because of CLI. McDermott et
al5 demonstrated that many patients traditionally classified
as having Fontaine stage I disease are not asymptomatic but
manifest a variety of lower extremity symptoms other than
claudication not currently considered typical symptoms of
lower extremity vascular disease. The extensive comorbid
conditions that accompany CLI in many patients, eg, dia-
betes, coronary artery disease, and chronic obstructive pul-
monary disease, may restrict their activities sufficiently to
preclude any claudication before CLI onset. The most
reproducible natural history data from the surgical litera-
ture of CLI report a 50% to 60% 5-year patient survival
rate,6-10 but in selected series survival was lower.11-13 Pa-
tients with CLI and end-stage renal disease have an even
worse survival rate.14 In view of this markedly increased
mortality, surgical care for most patients with CLI must be
considered highly palliative. Obviously, the risk-benefit
ratio for interventions in asymptomatic conditions in this
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population (eg, coexistent carotid disease, graft surveil-
lance) needs to be carefully weighed. Equally important is
weighing the potential morbidity of therapy in palliative
care. Currently unanswered questions include the follow-
ing: Is it really acceptable to strive for the greatest patency
and limb salvage rates in a population with abbreviated
survival when doing so frequently is associated with signif-
icant morbidity? Is it reasonable to have up to 10% to 15%
mortality before incision and target wound healing?15,16 Is
CLI, in reality, more important as a marker for early mor-
tality from end-stage atherosclerosis and the initial symp-
tom of limb threat actually a secondary consideration?
EXAGGERATED ROLE OF
REVASCULARIZATION
We believe the reported success for lower extremity
revascularization for CLI can be summarized as follows: (1)
Modern anesthesia and perioperative care have reduced
operative mortality rates to 5% or less. (2) Centers of
excellence report 5-year assisted primary patency rates of
70% to 90% for bypass grafting to the above-knee and
below-knee popliteal arteries using saphenous vein (re-
versed or in situ). Similarly, 5-year assisted primary patency
rates of 60% and greater have been reported for tibial and
pedal bypass grafting using saphenous vein. Slightly re-
duced 5-year patency rates have been reported for alternate
vein bypass grafting, with up to 30% need for graft surveil-
lance revisions. (3) Multiple operative series demonstrate
5-year limb salvage of 80% and greater.6-10,15,17-22 The
current surgical database regarding the efficacy of lower
extremity revascularization needs to be placed in perspec-
tive. Clearly, large referral centers in multiple geographic
locations have reported excellent technical results in pre-
serving limbs using alternate vein conduits, spliced vein
segments, and conducting distal anastamoses to tibial and
pedal targets.8-10,13,17-20,22-24 However, when scrutinized,
these data reflect only a subgroup of the vascular centers in
the United States most expert in the management of CLI.
Most of these reports arise from a handful of very active
centers within this subgroup. Thus these reports may lack
generalizability. The actual state of the art regarding lower
extremity revascularization throughout the United States
(and Europe) is less clear. Evidence from statewide Medi-
care surveys regarding carotid endarterectomy indicates
that the highly expert referral centers are actually the out-
liers nationwide, and global efficacy is less than the “best”
reported surgical series.25,26 It would be reasonable to
assume a similar situation with regard to lower extremity
arterial bypass grafting.
Lower extremity arterial bypass surveillance programs
have been widely accepted based on work from expert
centers demonstrating efficacy in predominately asymp-
tomatic graft lesion detection and repair.27-33 However,
graft surveillance can be considered a postoperative mor-
bidity because it increases the effects on the patient and the
cost of the procedure.34 Despite the reported success with
graft surveillance, no randomized trials clearly demonstrate
that aggressively treating all asymptomatic graft lesions
leads to an increase in graft patency and limb salvage.
Although many experts believe a randomized trial is unnec-
essary, one must keep in mind the early skepticism regard-
ing the need for the recently reported Veterans Affairs
Small Aneurysm Trial.35 One fact that is indisputable is that
these are usually asymptomatic lesions in patients with
limited life expectancy who are then undergoing potentially
morbid procedures.
The study of the chronic morbidity of revascularization
because of CLI is in its infancy. It appears that up to 25% of
patients have some type of incisional wound complication
postoperatively.15,36,37 Some require repeat operations,
and all bear the pain and expense of extensive wound care.
In up to 1% of all patients who undergo revascularization a
graft infection will develop secondary to wound break-
down, with a 15% mortality rate and 40% incidence of
major limb loss.38-40 Postoperative lymphedema is consid-
ered an important factor in prolonging incisional healing
and patient discomfort.21 Control of pain is clearly a critical
issue for palliative care, yet the incidence of postoperative
ischemic neuropathy, iatrogenic operative nerve injury, and
the effect of chronic nonhealing incisional and foot wounds
are little understood.
ROLE OF PRIMARY AMPUTATION
STRATEGIES: IMPACT ON FUNCTION
There are similar deficiencies in our knowledge regard-
ing amputation because of CLI. The above-knee amputa-
tion (AKA)–below knee amputation (BKA) ratio is roughly
1:1 and has not changed in several decades.41-46 The
perioperative mortality rate for BKA is 5% to 10% and for
AKA is 10% to 15%, due to comorbid conditions in the
population with end-stage disease currently receiving this
therapy.47,48 Primary incisional healing is far greater with
AKA than with BKA.49-51 In as many as a third of BKA
procedures, secondary operations will be required in an
attempt to achieve healing, and half of these ultimately will
be converted to AKA.46 Independent ambulation at 1 year
in vascular amputees is negligible for AKA and 10% to 25%
for BKA, with a steady attrition rate over time due to
multiple factors.44
Despite these data, the functional status and level of
independence in the CLI population is largely unknown.
Extensive comorbid conditions, eg, diabetes, cardiac dis-
ease, and pulmonary disease, likely limit ambulation even in
the absence of ischemic rest pain or ulceration. Thus even a
successful operation or angioplasty may not improve func-
tional status or relieve suffering in all patients. Most vascu-
lar surgeons would agree that an edematous extremity with
some degree of pain and slowly healing wounds is a reason-
able expectation for the first 3 months after successful
revascularization. Some of these patients will recover with
minimal additional problems and survive for many years.
However, in selected high-risk patients an early amputation
with the remainder of the patient’s life focused on home
and social activities may be time better spent than weeks of
hospitalization to repair failed distal bypass procedures or in
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the clinic attempting to heal distal wounds. At this time, we
simply do not know.
EFFECT OF ISCHEMIC ULCERATION ON
OUTCOME
Very little is known regarding the degree to which the
extent of foot lesions influences morbidity, ultimate suc-
cess, and functional outcome of limb salvage attempts in
patients with CLI. Selected reports describe collective series
of lower extremity bypass procedures with mid-foot ampu-
tation52 and free-flap tissue transfer to salvage extensively
involved lesions of the forefoot or heel,53,54 but these
approaches must currently be considered the exception
rather than the rule. Aggressive foot salvage in CLI with
severe necrosis frequently requires multiple foot opera-
tions, prolonged wound care, and healing time measured in
months rather than weeks. It seems intuitive that there is a
point where the morbidity of this approach exceeds any
long-term benefit. A tremendous amount of research has
been focused on defining pedal circulation limits (eg, toe
pressure, pulse volume recordings, transcutaneous oxygen
tension) that would be adequate to support local wound
healing, with minimal consideration of the nature of
wounds this marginal circulation should support.
EFFECT OF SYSTEMIC ATHEROSCLEROSIS ON
OUTCOME
Could aggressive risk factor modification in patients
with CLI improve 5-year survival rates, or do these patients
have such extensive systemic atherosclerosis that their mor-
tality risk cannot be modified? Does chronic lower extrem-
ity ischemia manifested by unhealed wounds, graft throm-
bosis, or stenosis actually promote fatal ischemic events in
this population because of a systemic inflammatory state
with oxygen free radical generation that promotes coronary
plaque instability? Evidence in the coronary literature sup-
ports this mechanism.55 Is there actually an inverse rela-
tionship between limb salvage and survival in patients with
CLI? Would survival actually be improved by a more judi-
cious approach to high-risk revascularization (tenuous re-
vascularization due to conduit or target arteries, or large
foot lesions), resulting in early amputation of some limbs at
high risk for recurrent or ongoing ischemia? We currently
do not have data to permit a definitive answer to any of
these important questions.
PROPOSED APPROACH TO PATIENT
MANAGEMENT
If subgroups of patients with CLI are better served by
amputation, how can they be identified? A possible ap-
proach is to look at the problem from three sides: technical
issues of revascularization, foot wound healing issues, and
comorbidity. Patients with marginal prospects in more than
one category would not be considered reasonable revascu-
larization candidates. Therefore alternate vein conduit for a
tibial bypass would be reasonable for a patient with man-
ageable toe gangrene and modest comorbidity, but would
not be reasonable for a patient receiving home oxygen
therapy or with a large heel defect. Subgroups with severe
comorbid conditions, who may survive the procedure be-
cause of modern anesthesia but are unlikely to survive the
follow-up required to heal incisions and wounds and the
rehabilitation process, would also not be offered extensive
limb salvage. Perhaps other clinical markers are needed.
Preoperative C- reactive protein levels have been used to
predict patient survival, foot healing, and limb salvage.56,57
Low serum albumin levels have correlated with mortality
and increased length of stay in multiple studies of elderly
hospitalized patients.58-60 We are not aware of any reports
examining this marker in a series of distal bypass proce-
dures.
Prospective natural history studies are needed to close
the gap between asymptomatic patients with significant
arterial occlusive disease and patients with CLI. Screening
for patients with Fontaine I disease with significantly re-
duced ankle brachial indices with or without other risk
factors and then observing them for onset of CLI in a
multicenter study would greatly enhance our currently
limited data base by providing insight into at-risk popula-
tions. A randomized trial of graft surveillance is in order.
Multicenter clinical trials of limb salvage versus amputation
in high-risk groups (eg, patients with renal failure, repeat
operations, extensive foot necrosis, poor nutrition, exten-
sive comorbidity) focusing on wound healing and function
are needed. Similar trials for aggressive risk factor modifi-
cation (eg, anti-platelet, lipid control, blood pressure con-
trol) and mortality reduction in CLI populations are in
order.
Clinical data are always available for the comorbid
conditions our patients have, but do we really use this
information in practice? Does a patient’s nutritional status,
pulmonary status, ejection fraction, body mass index, or
hemoglobin level, all of which have tremendous functional
and some survival implications, really factor into our deci-
sion making about limb salvage? Or is our attention forever
fated to be concerned only with availability of autogenous
conduit and the arteriographic findings? The late Dr. John
Porter stated on more than one occasion, “The last three
decades in limb salvage surgery we discovered what we
could do. Now it is time to learn what we should do.”
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